The Clinicopathologic Pattern of Prostatic Carcinoma in Lagos, Nigeria

M. Olatokunboh Odubanjo, Adekunbiola AF. Banjo, Shonibare Ayoola, Fatimah B. Abdulkareem, Chidozie C. Anunobi, Afolabi A. Olayinka


This is a review of the clinicopathological pattern of prostatic carcinoma in Lagos, Nigeria. The mean age was 68.48 years.  20% of our patients were asymptomatic at presentation, significantly higher than values from most previous Nigerian studies, likely due to an established PSA screening program.  This however did not appear to translate to better disease outcomes, likely because radical prostatectomy was not offered as a treatment option for early disease.  68.6% of symptomatic patients presented with lower urinary tract symptoms, and 4.4% had a family history of prostate cancer. The median PSA value at presentation was 58.90ng/ml.  Clinical stages II and III disease were most common, 42.5 and 30% respectively.  Gleason scores 6 and 8 were the most common (23.3 and 20% respectively).  The clinical stage and the age showed the best correlation with disease progression evidenced by increased PSA 2 months after treatment (PSA progression) and metastasis during follow up.  The Gleason score also showed good correlation with these parameters while the pre-treatment PSA showed poor correlation, possibly due to the high incidence of urogenital infections and prostatitis in this environment.  The incidence of PSA progression and metastasis were 0.35 and 0.54 per patient year of follow up respectively.  


clinicopathologic pattern, prostatic carcinoma, Nigeria

Full Text:



Epstein JI, Alagba F, Allsbrook Jr WC, et al. Acinar adenocarcinoma/ Tumours of the prostate (Chapter 3), Eds: Eble JN, Sauter G, Epstein JI, et al. Tumours of the Prostate (Chapter III), Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, World Health Organization Classification of Tumours, Lyon, France, IARC Press, 2004, 162-192.

Mohammed AZ, Edino ST, Ochicha O, et al. Cancer in Nigeria: a 10-year analysis of the Kano cancer registry. Niger J Med. 2008;17(3):280-284.

Cancer Incidence and Mortality Statistics for 2008, Cancer Fact Sheets for Nigeria, GLOBOCAN 2008, International Agency for Research on Cancer (IARC) © World Health Organization, 566-568, 2009.

Carroll P, Shinohara K. Transrectal ultrasound guided prostate biopsy.

Humphrey PA. Prostate/ Chapter 29, Section VII. Reproductive tract, Eds. Humphrey PA, Dehner LP, Pfeifer JD, The Washington Manual of Surgical Pathology, Missouri, United States of America, Lippincott Williams & Wilkins, 2008, 375-389.

Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, Springer-Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/

Hong Kong, 2002 (6th ed). Prostate (Chapter 34). 309-316.

Humphrey PA. Gleason grading and prognostic factors in carcinoma of

the prostate, Modern Pathology. 2004;17(3):292-306.

Buhmeida A, Pyrhönen S, Laato M, et al. Prognostic factors in prostate cancer. Diagn Pathol. 2006;1:4.

Pinchot H, Strum SB. The Clinical Stage: Its Definition and Importance in Prostate Cancer, PCRI Insights 3:8-9,2000.

Moul JW, Banez LL, Freedland SJ. Rising PSA in Nonmetastatic Prostate Cancer, Oncology. 21,1,2007.

prostatecancer/content/article/10165/63133. Acccessed on 4/1/2013.

Onuigbo WIB. Carcinoma of the prostate: Indigenous patterns, Journal of the National Medical Association. 1984;76(2):373-375.

Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Africans. BJU Int. 2000;85(9):1074-1077.

Ogunbiyi JO, Shittu OB. Increased Incidence of Prostate Cancer in Nigerians. J Natl Med Assoc. 1999;91(3):159-164.

Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. J Natl Med Assoc. 2002;94(7):619–627.

Badmus TA, Adesunkanmi AR, Yusuf BM, et al. Burden of Prostate Cancer in Southwestern Nigeria. Urology. 2010;76(2):412-416.

SEER Stat Fact Sheet for prostate cancer ©National Cancer Institute, United States National Institutes of Health. Accessed on 4/1/2013.

Dawam D, Kalayi GD, Osuide JA, et al. Haematuria in Africa: is the pattern changing? BJU International. 2001;87(4):326-330.

Yawe KT, Tahir MB, Nggada HA. Prostate cancer in Maiduguri. West Afr J Med. 2006;25(4):298-300.

Olapade-Olaopa EO, Obamuyide HA, Yisa GT. Management of advanced prostate cancer in Africa. Can J Urol. 2008;15(1):3890-3898.

Jackson MA, Kovi J, Heshmat MY, et al. Characterization of prostatic carcinoma among blacks: a comparison between a low-incidence area, Ibadan, Nigeria, and a high-incidence area, Washington, DC. Prostate. 1980;1(2):185-205.

Ajape AA, Ibrahim KO, Fakeye JA, Abiola OO. An overview of cancer of the prostate diagnosis and management in Nigeria: The experience in a Nigerian tertiary hospital. Ann Afr Med. 2010;9(3):113-117.

O’Dowd GJ, Veltri RW, Miller MC, Strum SB. The Gleason Score: A Significant Biologic Manifestation of Prostate Cancer Aggressiveness On Biopsy. Reprinted from PCRI Insights January 2001 v4.1.

Freeman VL, Leszczak J, Cooper RS. Race and the histologic grade of prostate cancer. Prostate. 1997;30(2):79-84.

Abbiyesuku FM, Shittu OB, Oduwole OO, et al. Prostate specific antigen in the Nigerian African. Afr J Med Med Sci. 2000;29(2):97-100.

Moul JW, Connelly RR, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999;162(2):394-397.

Fact sheet on Prostate specific antigen (PSA) test © National Cancer Institute at the National Institutes of Health, USA, vailable at

Magoha GA. Subcapsular orchidectomy in the management of prostatic carcinoma in Nigerians, East Afr Med J. 1989;66(6):400-403.

Epstein JI. Gleason Score 2–4 Adenocarcinoma of the Prostate on Needle Biopsy- A Diagnosis That Should Not Be Made (Editorial). Am J Surg Pathol. 2000;24(4):477–478.

Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244.

Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.

Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol. 2002;167(1):103-111.

Okolo CA, Akinosun OM, Shittu OB, et al. Correlation of Serum PSA and Gleason Score in Nigerian Men with Prostate Cancer, African Journal of Urology. 2008;14(1):15-22.

Yu JB, Makarov DV, Sharma R, et al. Validation of the Partin nomogram for prostate cancer in a national sample. J Urol. 2010;183(1):105-111.


  • There are currently no refbacks.